Now I have all the evidence I need. Let me synthesize the final review.

## Summary
2-3 sentence summary of the paper's contribution.

## Strengths
- strength 1 with evidence
- strength 2 with evidence

## Weaknesses
### Fatal
### Major
### Minor
### Trivial

## Nice-to-Haves

## Removed Points

## Novel Insights

## Suggestions

## Score and Decision

Let me produce the final review.

---

## Summary

The paper presents NormIntSleep, a framework that projects deep neural network embeddings onto a clinically-grounded feature space (FeatShort, designed per AASM guidelines) and then trains interpretable glass-box models (decision trees, CatBoost, XGBoost) on those projected representations. It also introduces AlignmentDT, a metric to quantify how well a decision tree's splits align with domain knowledge. The central contribution is demonstrating that combining DNN representational power with a clinically-relevant feature space yields interpretable models that substantially outperform using the clinical features alone (e.g., NormIntSleep-DecisionTree improves accuracy over FeatShort-DecisionTree by ~6-9 percentage points across two datasets) while maintaining decision paths that mirror clinical practice.

## Strengths

- **Large, well-documented accuracy gains for the most interpretable model (decision tree):** NormIntSleep-DecisionTree improves accuracy over FeatShort-DecisionTree (the same clinical feature set but without the DNN projection) by 6.1 points on PhysioNet (75.8% → 81.9%) and 9.3 points on ISRUC (69.8% → 79.1%) (Section 5, paragraph 1). This directly demonstrates that the DNN projection adds clinically-relevant information beyond what handcrafted features alone provide, while maintaining a fully transparent decision tree.

- **Clinician-validated decision tree that mirrors AASM guidelines:** A practicing sleep clinician reviewed the NormIntSleep-DecisionTree and confirmed that each split (beta waves for Wake, EOG crossings for wake/REM, EMG complexity for Wake, EEG kurtosis for REM, slow waves for N3) corresponds directly to AASM manual guidelines (Section 5.1, bullet-pointed observations). This external validation grounds the interpretability claims in actual clinical practice rather than relying solely on automated metrics.

- **AlignmentDT provides a quantitative, comparable measure of domain-grounding:** The metric successfully discriminates between methods: NormIntSleep-DecisionTree scores 1.0, SERF scores 0.44, and FeatLong-DecisionTree scores 0 (Section 5.1, final paragraph). This gives the community a concrete way to compare methods on the dimension of clinical alignment, which existing metrics (accuracy, F1, κ) do not capture.

- **SHAP analysis provides convergent evidence:** The top-5 most important features of NormIntSleep-XGBoost (EOG complexity and kurtosis for REM, beta waves for Wake, EEG variance for N3) align with clinical knowledge and are consistent with the decision tree paths, providing a second independent validation that the interpretable representations carry clinically meaningful information (Section 5.3, Figure 3).

## Weaknesses

### Fatal
None.

### Major
- **Abstract overclaims performance relative to acknowledged comparison.** The abstract states that NormIntSleep "outperforms prior interpretable techniques" with accuracy/F1/κ ranges, without qualification. However, Section 5 reports that FeatLong-CatBoost (a feature-based interpretable method) achieves higher top-end accuracy (0.862 vs. 0.847) and F1 (0.811 vs. 0.793) than NormIntSleep-CatBoost. The paper's main text honestly acknowledges this ("with the sole exception of the exhaustive feature list present in FeatLong," Section 5, paragraph 1), but the abstract suppresses this qualification, misleading a reader about the nature of the advantage. The real differentiator is clinical alignment (AlignmentDT), not raw accuracy—the abstract should reflect this.

- **Experimental design uses only a single train-test split with no cross-validation reported in the main text.** The paper partitions data by subjects into a single 9:1 split using one seed (Section 4.1). With ≤100 subjects per dataset, results could be sensitive to how the split lands. The paper states confidence intervals are in Appendix I, but the main text does not report any measure of variance (standard deviation, confidence intervals, or multiple runs), making it impossible for the reader to assess the stability of the reported metrics from the main results alone. This limits the evidential weight of the performance comparisons.

### Minor
- **AlignmentDT is defined in terms of the pre-selected FeatShort feature set, creating a self-referential evaluation.** Since NormIntSleep explicitly projects DNN embeddings into the FeatShort space, any decision tree built on those representations will naturally use FeatShort features, yielding a perfect score by construction on that dimension. The metric does not independently validate that the resulting explanations are clinically *correct*—it checks whether they use the pre-chosen features. The paper partially addresses this through the clinician review (Section 5.1), but that review is a single expert's opinion and not systematically quantified. Positioning AlignmentDT as a consistency or adherence metric (rather than an independent validity metric) would be more accurate.

- **The trade-off between the most interpretable variant (decision tree, ~79% accuracy) and the top-performing variants (CatBoost/XGBoost, ~81–85% accuracy) is not clearly discussed.** The paper presents both the decision tree (fully transparent, AlignmentDT=1.0, lower accuracy) and boosting variants (higher accuracy, less transparent as ensembles) under the NormIntSleep umbrella, but does not explicitly state which variant the authors recommend for clinical use or acknowledge the interpretability-accuracy trade-off within the framework itself.

- **No discussion of faithfulness:** NormIntSleep guarantees that the glass-box model's input is in the FeatShort space, but it does not guarantee that the DNN's own decision process is aligned with those features. The DNN could rely on completely different signal characteristics while the glass-box model uses FeatShort features. This gap between the DNN's internal representations and the glass-box model's explanations is not discussed.

### Trivial
- The range format (e.g., "0.814–0.847") is not labeled in the main text as min-max across datasets versus across runs; the interpretation is inferable from context but should be stated explicitly.
- The AlignmentDT equation is referenced (Eq. 1) but not shown in the extracted text (likely a rendering issue), and its definition in Section 3.4 is cut off.

## Nice-to-Haves
- **Multiple train-test splits or cross-validation** with mean ± std reported (even if partial, e.g., 5-fold on one dataset) would substantially strengthen the statistical grounding of the results.
- **Ablation replacing DNN embeddings with random projections** of the same dimensionality would help quantify how much of the decision tree improvement comes from learned DNN representations versus the projection mechanism itself.
- **Validation of AlignmentDT with multiple clinicians** (reporting inter-rater agreement) would make the interpretability claims more convincing and less dependent on a single expert's judgment.
- **Comparison to post-hoc explanations (e.g., SHAP on the raw DNN)** would help contextualize whether NormIntSleep's inherently interpretable explanations are preferable to explaining the black-box DNN directly.

## Removed Points
These points are flagged to be removed; treat them with caution.

- **"Glass-box terminology used loosely"** — The paper uses "glass-box" for decision trees, CatBoost, and XGBoost. This terminology is standard in the interpretable ML literature where "glass-box" contrasts with opaque DNNs. The critique is a terminology preference rather than a substantive flaw.
- **"No comparison to post-hoc explanation methods (LIME, SHAP on the DNN)"** — The paper *does* use SHAP for feature importance analysis (Section 5.3), which is a form of post-hoc explanation. The request for LIME or SHAP on the *raw DNN* specifically is a scope-expansion suggestion, not a missing baseline for the paper's stated contribution (which is about inherently interpretable models).
- **"Features like complexity, mobility are generic statistical properties"** — The paper explicitly links each feature to AASM guidelines (Table in Section 3.3), including citations for the clinical relevance of complexity and mobility. The criticism ignores these connections.
- **"Missing related works"** — As per instructions, I cannot verify whether related works are missing and do not include such criticisms.
- **"Reproducibility details missing for glass-box models"** — Tree depth is explicitly stated (depth=4, Figure 2 caption). For CatBoost/XGBoost, default parameters are a reasonable starting point given the paper uses scikit-learn interfaces. This is a minor completeness issue at most.
- **"Dimensionality mismatch between FeatShort and FeatLong"** — The difference in dimensionality (52-121 vs 1048-2488) is a design choice, not a confounding factor. The paper explicitly contrasts the small, clinically-grounded feature set against the large, exhaustive one. This is the intended comparison.

## Novel Insights

None beyond the paper's own contributions. The two reviews largely agree on the paper's strengths (the decision tree accuracy improvement, clinician validation, AlignmentDT metric) and weaknesses (abstract overclaim, single train-test split, self-referential aspect of AlignmentDT). One insight emerges from juxtaposing the harsh critic's concern about FeatLong-CatBoost outperforming NormIntSleep-CatBoost on raw accuracy with the strength finder's emphasis on AlignmentDT: the paper's real contribution is not that NormIntSleep is more accurate than all prior interpretable methods (it isn't, on the top end), but that it achieves competitive accuracy *while* offering demonstrably better clinical alignment. This distinction should be sharpened in the paper's framing.

## Suggestions

1. **Revise the abstract** to accurately frame the contribution: NormIntSleep achieves competitive accuracy with prior interpretable methods while providing substantially better clinical alignment (AlignmentDT=1.0 vs. ≤0.44). Remove or qualify the unqualified "outperforms" claim.
2. **Report at least one measure of variance** (e.g., 95% confidence intervals or results across 3-5 different seeds) in the main results table, even if full cross-validation is deferred to the appendix.
3. **Position AlignmentDT explicitly** as a measure of adherence to a pre-defined clinically-relevant feature set, not as an independent validation of clinical correctness. Combine it with the clinician review for a stronger two-part evaluation.
4. **State the accuracy-interpretability trade-off clearly:** recommend the decision tree variant for scenarios where full transparency is required, and the boosting variants for scenarios where higher accuracy is needed and ensemble-level interpretability is acceptable. Make it explicit that the paper's strongest evidence for interpretability applies to the decision tree.

## Score and Decision

MY FINAL SCORE: <score>6.5</score>
MY FINAL DECISION: <decision>Accept</decision>